The sell-off of this pharmaceutical giant might be overdone. Once a market darling during the early pandemic years, Pfizer ( ...

Pfizer CEO Albert Bourla is expected at a pro-Trump fundraiser on Friday, sources told CBS News, one day after the president ...

In terms of fundamentals, Pfizer currently boasts a market capitalization of $132 billion. Over the last twelve months, the ...

Pfizer will report its fiscal second-quarter earnings on Aug. 5. Although we won't know if it'll continue its beats streak ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Pfizer faces weak growth, sector headwinds, and pipeline uncertainty despite cost cuts and a 7% yield, weighing on sentiment.

Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large cap stocks ...

BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

A U.K. Court of Appeals ruling confirms the validity of a patent covering modifications of mRNA used in Moderna’s vaccines.

Turkish scientists say that Pfizer's COVID-19 vaccine can increase the risk of eye damage, causing vision loss. A new study examined how the vaccine affected patients' corneas—the clear front of the ...